Conventional induction and maintenance treatment of Antineutrophil cytoplasmic antibodies-associated vasculitis - still of value for our patients?

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10296534" target="_blank" >RIV/00216208:11110/15:10296534 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/15:10296534

Výsledek na webu

<a href="http://dx.doi.org/10.1517/14656566.2015.1059822" target="_blank" >http://dx.doi.org/10.1517/14656566.2015.1059822</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1517/14656566.2015.1059822" target="_blank" >10.1517/14656566.2015.1059822</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Conventional induction and maintenance treatment of Antineutrophil cytoplasmic antibodies-associated vasculitis - still of value for our patients?

Popis výsledku v původním jazyce

Introduction: Antineutrophil cytoplasmic antibodies-associated vasculitis (AAV) is a group of autoimmune diseases characterized by the necrotizing inflammation of small vessels and associated with the antineutrophil cytoplasmic antibodies. Treatment of AAV can be divided into the induction phase aimed at achieving remission of the disease and the maintenance phase aimed at prevention of relapses. Long-term outcome of AAV dramatically improved with the introduction of cyclophosphamide. Recent clinical studies resulted in the reduction of the cumulative dose of cyclophosphamide and introduction of new treatment options, namely B-cell-depleting antibody rituximab, into both induction and maintenance treatment. This paper aims to evaluate the current roleof the conventional induction and maintenance treatment in view of the gradually increasing use of rituximab. Areas covered: This paper provides an overview of the main clinical studies in induction and maintenance treatment of adult pati

Název v anglickém jazyce

Conventional induction and maintenance treatment of Antineutrophil cytoplasmic antibodies-associated vasculitis - still of value for our patients?

Popis výsledku anglicky

Introduction: Antineutrophil cytoplasmic antibodies-associated vasculitis (AAV) is a group of autoimmune diseases characterized by the necrotizing inflammation of small vessels and associated with the antineutrophil cytoplasmic antibodies. Treatment of AAV can be divided into the induction phase aimed at achieving remission of the disease and the maintenance phase aimed at prevention of relapses. Long-term outcome of AAV dramatically improved with the introduction of cyclophosphamide. Recent clinical studies resulted in the reduction of the cumulative dose of cyclophosphamide and introduction of new treatment options, namely B-cell-depleting antibody rituximab, into both induction and maintenance treatment. This paper aims to evaluate the current roleof the conventional induction and maintenance treatment in view of the gradually increasing use of rituximab. Areas covered: This paper provides an overview of the main clinical studies in induction and maintenance treatment of adult pati

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FE - Ostatní obory vnitřního lékařství

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Expert Opinion on Pharmacotherapy

ISSN

1465-6566

e-ISSN

—

Svazek periodika

16

Číslo periodika v rámci svazku

11

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

20

Strana od-do

1683-1702

Kód UT WoS článku

000358458400011

EID výsledku v databázi Scopus

2-s2.0-84936946970